Ravulizumab Ultomiris®
The SHIKARI® Ravulizumab portfolio supports quantitative analysis of free ravulizumab and quantitative measurement of antibodies to ravulizumab in human serum or plasma.
Why Ravulizumab is relevant to biological-drug monitoring research
Ravulizumab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Molecular Target & Structure
Ravulizumab is a long-acting humanised monoclonal antibody that binds complement protein C5 and inhibits terminal complement activation. Source ↗
Approved Indications
EMA-authorised uses include paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, AChR-antibody-positive generalised myasthenia gravis and AQP4-antibody-positive neuromyelitis optica spectrum disorder in defined patients. EMA source ↗
Maintenance Exposure
Regulatory data demonstrate high sustained serum concentrations under weight-based maintenance regimens:
Regulatory exposure values are regimen- and population-specific and are not therapeutic targets. Values vary with dose, timing, formulation and study population. This page is for RUO product information and does not provide clinical guidance.
Two verified Ravulizumab research assays
Ligand-binding, sandwich-principle ELISA for quantitative analysis of free ravulizumab in human serum or plasma.
Quantitative ELISA for antibodies to ravulizumab in human serum or plasma, including the assay-specific confirmation-reagent procedure.
Verified Specifications at a Glance
| Kit | REF | Mode | Analyte | Sample | Volume | Time | Analytical output | Tests | Shelf life | Storage | Shipping |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SHIKARI® Q-RAV | RAV-FD-ULT | Quantitative | Free ravulizumab | Human serum / plasma | 10 µL | 70 min | LOD 18.75 ng/mL; LOQ 20 ng/mL | 96 | 6 months | 2–8°C | 10–30°C |
| SHIKARI® S-ATRAV | RAV-QNS-ULT | Quantitative | Antibodies to ravulizumab | Human serum / plasma | 50 µL | 140 min | LOD 15 ng/mL; LOQ 20 ng/mL | 96 | 1 year | 2–8°C | 10–30°C |
Analytical specifications are summarised from the current controlled IFUs and exact official product records. Standard curves are official illustrative product images and must not be used for sample quantification. Follow the link on each assay card for the corresponding product record on matriksbiotek.com.
Match the assay to the research question
Choose among the two assays according to the analytical output required by the study.
Ravulizumab Literature and Product-Use Records
Planning a Ravulizumab research study?
Matrix Biotek can help identify the appropriate Ravulizumab assay and prepare regional quotation and delivery information. SHIKARI® products are developed and manufactured in Ankara and supported through our European headquarters in Barcelona.